A Central Illinois cardiologist breaks down the potential benefits of GLP-1 medications on heart health. It was one of the ...

Are GLP-1 therapies truly safe for long-term cardiovascular health? Dr Pandey unpacks key gaps in current research, ...

If obesity is seen not just as a personal struggle but a disease of public health concern, we can look for systemic solutions ...

How should you guide patients on GLP-1 therapy who are planning pregnancy? Dr Almandoz breaks down when to stop treatment, ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...

In this randomized controlled trial, insulin alfa efsitora (efsitora) demonstrated noninferiority to degludec in reducing ...

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...

In recent years, the landscape of diabetes and weight management has been significantly altered by the rise of glucagon-like peptide-1 (GLP-1) receptor agonists. These medications, initially developed ...

Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...

Consumers taking GLP-1 drugs like Ozempic will need to adapt their shopping habits and diets, opening opportunities for food ...